Clinical manifestations and treatment of HIV related non-Hodgkin lymphoma.
Donald W. Northfelt, Lawrence D. Kaplan
Abstract
Donald W. Northfelt, Lawrence D. Kaplan
Abstract
Non-Hodgkin lymphoma developing in patients with HIV infection fulfills diagnostic criteria for AIDS. Clinical manifestations of AIDS-NHL are similar to those of malignant lymphoma arising in other acquired and congenital immunodeficiency states. AIDS related NHLs therefore consist primarily of tumours with B cell phenotype, intermediate or high grade histological subtype and rapid clinical progression with a high frequency of unusual extranodal involvement. Treatment of AIDS-NHL has been much less rewarding than treatment of lymphoma in non-HIV infected individuals. Complete response rates are lower than the corresponding rates seen in the non-HIV infected population, and responses that do occur tend to be of short duration. Improvements in treatment for AIDS-NHL will require the use of new therapies, designed to cause less myelosuppression, in conjunction with aggressive efforts to prevent opportunistic infections.
OpenAlex reports 18 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Non-Hodgkin lymphoma developing in patients with HIV infection fulfills diagnostic criteria for AIDS. Clinical manifestations of AIDS-NHL are similar to those of malignant lymphoma arising in other acquired and congenital immunodeficiency states. AIDS related NHLs therefore consist primarily of tumours with B cell phenotype, intermediate or high grade histological subtype and rapid clinical progression with a high frequency of unusual extranodal involvement. Treatment of AIDS-NHL has been much less rewarding than treatment of lymphoma in non-HIV infected individuals. Complete response rates are lower than the corresponding rates seen in the non-HIV infected population, and responses that do occur tend to be of short duration. Improvements in treatment for AIDS-NHL will require the use of new therapies, designed to cause less myelosuppression, in conjunction with aggressive efforts to prevent opportunistic infections.
Key concepts: Lymphoma, Medicine, Non-Hodgkin's lymphoma, Human immunodeficiency virus (HIV), Population, Hodgkin lymphoma, Immunology, Immunodeficiency